About us Contact Terms of Use Data Sources Publications FAQ

Female Cancers

Molecular Synopsis

OVERVIEW
Drugs and clinical candidates

11 drugs have received FDA approval for Female Cancers:

  • Bevacizumab
  • Bleomycin Sulfate
  • MOPP
  • Mechlorethamine
  • Niraparib

265 drugs have a clinical trial registered for Female Cancers.

2484 compounds have been tested in Female Cancers (2081 <= 500nM potency) .

Sources: cancer.gov , clinicaltrials.gov , ChEMBL .

Clinical trials
There are 1886 clinical trials for Female Cancers, 1019 of which have one or more drug interventions, 867 with no drug intervention.
Cell line models

There is 19 Cell Line Models for Female Cancers.

Source: COSMIC
Mapped terms

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Female Cancers:
  • Uterine Cervical Neoplasms
  • Genital Neoplasms, Female
  • Retroperitoneal Neoplasms
  • Vaginal Neoplasms
  • Peritoneal Neoplasms
The following terms have been mapped from cancer.gov to Female Cancers:
  • Hodgkin lymphoma in children. It is used to treat certain female patients and is often used with radiation therapy
  • Vulvar cancer
  • Malignant pleural effusion, malignant pericardial effusion, and malignant peritoneal effusion
  • Lesions that sometimes lead to anal, cervical, vaginal, or vulvar cancer
  • Squamous cell carcinoma of the vulva